Influence of supplementing chemotherapy with Yiqi Fuzheng Xiaoji Formula on the quality of life and side effects in advanced lung cancer patients with syndrome of qi stagnation and blood stasis
GUO Guanghui1 ZHENG Lan1 YANG Junshu1 WANG Qiyuan2 LI Yue1#br#
1.Department of Respiratory Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
2.Department of Oncology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China
Abstract：Objective To investigate the influence of supplementing chemotherapy with Yiqi Fuzheng Xiaoji Formula on the quality of life and side effects in advanced lung cancer patients with syndrome of qi stagnation and blood stasis. Methods A total of 120 advanced lung cancer patients with syndrome of qi stagnation and blood stasis admitted to Hubei Hospital of Traditional Chinese Medicine from May 2020 to December 2021 were selected and divided into chemotherapy group and combination group by random number table method, with 60 cases in each group. The chemotherapy group received chemotherapy alone (Cisplatin + Gemcitabine), and the combination group received supplementing chemotherapy with Yiqi Fuzheng Xiaoji Formula. Both groups were treated continuously for two months. The short-term efficacy, side effects, and quality of life before and after treatment were observed. Results The short-term clinical efficacy of the combination group was better than that of the chemotherapy group, and the objective remission rate and disease control rate were higher than those of the chemotherapy group, the differences were statistically significant (P＜0.05). The degree of leukopenia, thrombocytopenia, liver and kidney function injury, nausea, vomiting, peripheral neurotoxicity in combination group were less than those in chemotherapy group, and the differences were statistically significant (P＜0.05). After treatment, scores of physical function, role function, emotional function, cognitive function, and social function in both groups were higher than those before treatment, the scores of physical function, role function, emotional function, and social function in combination group were higher than those in chemotherapy group, and the differences were statistically significant (P＜0.05). Conclusion Supplementing chemotherapy with Yiqi Fuzheng Xiaoji Formula can reduce the side effects of drugs, enhance the anti-tumor effect, and improve the quality of life of advanced lung cancer patients with syndrome of qi stagnation and blood stasis, which has high clinical value.
郭光辉1 郑岚1 杨俊姝1 王琦苑2 李悦1. 益气扶正消积方辅助化疗对气滞血瘀型晚期肺癌患者生活质量及副作用的影响[J]. 中国医药导报, 2023, 20(10): 109-112,121.
GUO Guanghui1 ZHENG Lan1 YANG Junshu1 WANG Qiyuan2 LI Yue1. Influence of supplementing chemotherapy with Yiqi Fuzheng Xiaoji Formula on the quality of life and side effects in advanced lung cancer patients with syndrome of qi stagnation and blood stasis. 中国医药导报, 2023, 20(10): 109-112,121.
[1] Siegel RL，Miller KD，Fuchs HE，et al. Cancer statistics，2022 [J]. CA-Cancer J Clin，2022，72（1）：7-33.
[2] 杜凤华，孔维博，孔祥舟，等.靶向联合化疗与常规化疗治疗表皮生长因子受体基因突变肺腺癌患者的临床效果[J].安徽医学，2019，40（4）：366-369.
[3] 张成.祛毒扶正汤联合化疗治疗中晚期非小细胞肺癌的疗效及对患者癌因性疲乏、化疗耐受性的影响[J].四川中医，2019，37（1）：107-109.
[4] 焦建玮，张艳景，白玉杰.祛毒扶正汤联合化疗治疗中晚期肺癌临床疗效及对T细胞亚群，VEGF的影响[J].中华中医药学刊，2020，38（5）：186-189.
[5] 于秀荣，李慧杰，齐元富.中医外治法在肿瘤常见并发症及放化疗副反应中的应用[J].山东中医杂志，2019，38（2）：193-196.
[6] 朱文锋，袁肇凯.中医诊断学[M].北京：人民卫生出版社，2011.
[7] 中华中医药学会.中医内科常见病诊疗指南：中医病证部分[M].北京：中国中医药出版社，2008：141-143.
[8] 中华医学会肿瘤学分会，中华医学会杂志社.中华医学会肿瘤学分会肺癌临床诊疗指南（2021版）[J].中华肿瘤杂志，2021，43（6）：591-621.
[9] Oken MM，Creech RH，Tormey DC，et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group [J]. Am J Clin Oncol，1982，5（6）：649-655.
[10] Therasse P，Arbuck SG，Eisenhauer EA，et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors [J]. JNCI，2000，92（3）：205-216.
[11] 皋文君，刘砚燕，袁长蓉.国际肿瘤化疗药物不良反应评价系统：通用不良反应术语标准[J].肿瘤，2012，32（2）：142-144.
[12] Aaronson NK，Ahmedzai N，Bergman B，et al. The European Organisation for Research and Treatment of Cancer QLQ-C30：A quality-of-life instrument for use in international clinical trials in oncology [J]. J Natl Cancer Inst，1993，85（5）：365-376.
[13] 彭子珊，孔辉，鲍真，等.83例多发肺腺癌患者的临床病理学特征分析[J].中国癌症杂志，2021，31（5）：408-418.
[14] Kuo JC，Graham DM，Salvarrey A，et al. A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non- small-cell lung cancer [J]. Current Oncology，2020，27（2）：5651.
[15] 宋玮，李英，宋琼珠.XPF基因多态性与晚期非小细胞肺癌铂类联合化疗效果及不良反应的相关性研究[J].实用癌症杂志，2022，37（2）：208-212.
[16] Zhang L，Zhang F，Li G. Traditional Chinese medicine and lung cancer——From theory to practice [J]. Biomed Pharmacother，2021，137（1）：111381.
[17] Su XL，Wang JW，Che H，et al. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer [J]. Chin Med J，2020，133（24）：2987-2997.
[18] 潘龙赐，王晶，黄怡娴，等.大黄甘草汤结合穴位敷贴对非小细胞肺癌化疗致胃肠道反应的效果观察[J].中国药物与临床，2021，21（17）：2918-2922.
[19] 王振强，张庆江，陈晶晶，等.肺瘤消积方对痰瘀互结型非小细胞肺癌患者化疗不良反应的影响[J].上海中医药杂志，2021，55（4）：45-49.
[20] 左志通，徐书，孙燕，等.自拟泻肺消水汤治疗肺癌伴恶性胸腔积液的临床观察[J].中华中医药杂志，2021，36（10）：6262-6264.
[21] 张添威，陈卫建，张蓉映，等.基于“痰毒”理论探讨化痰解毒法对中晚期非小细胞肺癌患者带瘤生存的临床意义[J].中华全科医学，2019，17（12）：69-72，177.
[22] 郑艺，汪旻琦.益气养血法配合雷火灸防治原发性肺癌化疗后骨髓抑制疗效及对集落刺激因子水平的影响[J].现代中西医结合杂志，2020，29（3）：255-258，304.
[23] 李邦凯，纪浩南，王馨，等.养正消积胶囊辅助GP方案治疗晚期非小细胞肺癌临床研究[J].中国中医药信息杂志，2019，26（8）：12-17.
[24] 毛维，王瑞，华莎，等.化瘀通络方对肺癌微环境树突状细胞的影响及其相关机制[J].实用肿瘤杂志，2019，34（5）：410-416.
[25] 杨献光，孙阁阁，丁翠红，等.黄芩苷的生物学功能及作用机理[J].中国细胞生物学学报，2021，43（4）：850- 855.
[26] 王悦，田双双，刘晓谦，等.茯苓多糖的提取、结构及药理作用研究进展[J].世界中医药，2021，16（17）：2548- 2555.
[27] 黄建勇，李少光，李宇翔，等.石上柏抗肿瘤活性部位及其化学成分研究[J].福建医科大学学报，2013，47（1）：1-5.
[28] 李向东，董灵.康莱特注射液联合化疗对晚期非小细胞肺癌生活质量及骨髓抑制的影响[J].河北医学，2016， 22（4）：19-21.
京公网安备 11010502046598号